{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:06:59Z","timestamp":1777673219588,"version":"3.51.4"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2015,3,2]],"date-time":"2015-03-02T00:00:00Z","timestamp":1425254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001809","name":"Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81201628"],"award-info":[{"award-number":["81201628"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Complications from skeletal-related events (SREs) constitute a challenge in the care of cancer patients with bone metastasis (BM).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives.<\/jats:title>\n                  <jats:p>This study evaluated the comparative effectiveness of pamidronate, ibandronate, zoledronate, and denosumab in reducing the morbidity of SREs in cancer patients with BM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>Medline (1948 to January 2014), Embase (1980 to January 2014), the Cochrane Library (2014 issue 1), and Web of Science with Conference Proceedings (1970 to January 2014) were searched. Only randomized controlled trials assessing denosumab, bisphosphonates, or placebo in cancer patients with BM were included. The primary outcomes were SREs and SREs by type. The network meta-analysis (NMA) was performed with a random-effects Bayesian model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>The NMA included 14 trials with 10,192 patients. Denosumab was superior to placebo in reducing the risk of SREs (odds ratio [OR]: 0.49; 95% confidence interval [CI]: 0.31\u20130.75), followed by zoledronate (OR: 0.57; 95% CI: 0.41\u20130.77) and pamidronate (OR: 0.55; 95% CI: 0.41\u20130.72). Ibandronate compared with placebo could not reduce the risk of SREs. Denosumab was superior to placebo in reducing the risk of pathologic fractures (OR: 0.50; 95% CI: 0.32\u20130.79), followed by zoledronate (OR: 0.61; 95% CI: 0.43\u20130.86). Denosumab was superior to placebo in reducing the risk of radiation (OR: 0.51; 95% CI: 0.35\u20130.75), followed by pamidronate (OR: 0.67; 95% CI: 0.52\u20130.86) and zoledronate (OR: 0.70; 95% CI: 0.52\u20130.96).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>This NMA showed that denosumab, zoledronate, and pamidronate were generally effective in preventing SREs in cancer patients with BM. Denosumab and zoledronate were also associated with reductions in the risk of pathologic fractures and radiation compared with placebo. Denosumab was shown to be the most effective of the bone-targeted agents.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2014-0328","type":"journal-article","created":{"date-parts":[[2015,3,3]],"date-time":"2015-03-03T04:03:26Z","timestamp":1425355406000},"page":"440-449","source":"Crossref","is-referenced-by-count":51,"title":["Systematic Literature Review and Network Meta-Analysis Comparing Bone-Targeted Agents for the Prevention of Skeletal-Related Events in Cancer Patients With Bone Metastasis"],"prefix":"10.1093","volume":"20","author":[{"given":"Zhiyu","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Internal Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Internal Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaohong","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Internal Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Curtis","sequence":"additional","affiliation":[{"name":"Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoting","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Internal Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Internal Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Internal Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, People's Republic of China"},{"name":"Radiation Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2015,3,2]]},"reference":[{"key":"2021122309232817700_B1","doi-asserted-by":"crossref","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","article-title":"Clinical features of metastatic bone disease and risk of skeletal morbidity","volume":"12","author":"Coleman","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"suppl","key":"2021122309232817700_B2","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"2021122309232817700_B3","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"key":"2021122309232817700_B4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urolonc.2005.06.020","article-title":"Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis","volume":"24","author":"Saad","year":"2006","journal-title":"Urol Oncol"},{"key":"2021122309232817700_B5","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"2021122309232817700_B6","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","article-title":"Skeletal related events, bone metastasis and survival of prostate cancer: A population based cohort study in Denmark (1999 to 2007)","volume":"184","author":"N\u00f8rgaard","year":"2010","journal-title":"J Urol"},{"key":"2021122309232817700_B7","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s10549-011-1475-5","article-title":"Survival in breast cancer patients with bone metastases and skeletal-related events: A population-based cohort study in Denmark (1999-2007)","volume":"129","author":"Yong","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2021122309232817700_B8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","article-title":"Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions","volume":"42","author":"Weinfurt","year":"2004","journal-title":"Med Care"},{"key":"2021122309232817700_B9","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","article-title":"Impact of skeletal complications on patients\u2019 quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"2021122309232817700_B10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta8040","article-title":"A systematic review of the role of bisphosphonates in metastatic disease","volume":"8","author":"Ross","year":"2004","journal-title":"Health Technol Assess"},{"key":"2021122309232817700_B11","volume-title":"Xgeva [product information]. Annex 1: Summary of product characteristics"},{"key":"2021122309232817700_B12","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"2021122309232817700_B13","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122309232817700_B14","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309232817700_B15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/1741-7015-9-79","article-title":"Network meta-analysis-highly attractive but more methodological research is needed","volume":"9","author":"Li","year":"2011","journal-title":"BMC Med"},{"key":"2021122309232817700_B16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejca.2012.07.016","article-title":"Denosumab for treatment of bone metastases secondary to solid tumours: Systematic review and network meta-analysis","volume":"49","author":"Ford","year":"2013","journal-title":"Eur J Cancer"},{"key":"2021122309232817700_B17","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)","author":"Higgins","year":"2011"},{"key":"2021122309232817700_B18","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1524-4733.2008.00347.x","article-title":"Bayesian meta-analysis of multiple treatment comparisons: An introduction to mixed treatment comparisons","volume":"11","author":"Jansen","year":"2008","journal-title":"Value Health"},{"key":"2021122309232817700_B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v012.i03","article-title":"R2WinBUGS: A package for running WinBUGS from R","volume":"12","author":"Sturtz","year":"2005","journal-title":"J Stat Softw"},{"key":"2021122309232817700_B20","volume-title":"R: A language and environment for statistical computing. Reference index version 2.12"},{"key":"2021122309232817700_B21","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.dss.2012.10.005","article-title":"ADDIS: A decision support system for evidence-based medicine","volume":"55","author":"Van Valkenhoef","year":"2013","journal-title":"Decis Support Syst"},{"key":"2021122309232817700_B22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.prevetmed.2007.01.003","article-title":"Assessing the convergence of Markov Chain Monte Carlo methods: An example from evaluation of diagnostic tests in absence of a gold standard","volume":"79","author":"Toft","year":"2007","journal-title":"Prev Vet Med"},{"key":"2021122309232817700_B23","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J R Statist Soc B"},{"key":"2021122309232817700_B24","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"2021122309232817700_B25","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1111\/j.1742-1241.2009.02168.x","article-title":"Understanding heterogeneity in meta-analysis: The role of meta-regression","volume":"63","author":"Baker","year":"2009","journal-title":"Int J Clin Pract"},{"key":"2021122309232817700_B26","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1200\/JCO.1996.14.9.2552","article-title":"Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomized controlled trial","volume":"14","author":"Conte","year":"1996","journal-title":"J Clin Oncol"},{"key":"2021122309232817700_B27","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"2021122309232817700_B28","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1200\/JCO.1999.17.3.846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122309232817700_B29","first-page":"3383","article-title":"Efficacy of pamidronate in breast cancer with bone metastases: A randomized, double-blind placebo-controlled multicenter study","volume":"19","author":"Hultborn","year":"1999","journal-title":"Anticancer Res"},{"key":"2021122309232817700_B30","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"2021122309232817700_B31","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"2021122309232817700_B32","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"2021122309232817700_B33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"2021122309232817700_B34","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122309232817700_B35","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","article-title":"Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: A randomised, open label, non-inferiority phase 3 trial","volume":"15","author":"Barrett-Lee","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021122309232817700_B36","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"2021122309232817700_B37","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"2021122309232817700_B38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.3816\/CGC.2005.n.009","article-title":"Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer","volume":"4","author":"Saad","year":"2005","journal-title":"Clin Prostate Cancer"},{"key":"2021122309232817700_B39","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","article-title":"Pathologic fractures correlate with reduced survival in patients with malignant bone disease","volume":"110","author":"Saad","year":"2007","journal-title":"Cancer"},{"key":"2021122309232817700_B40","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3816\/CGC.2007.n.022","article-title":"Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases","volume":"5","author":"Saad","year":"2007","journal-title":"Clin Genitourin Cancer"},{"key":"2021122309232817700_B41","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J Clin Oncol"},{"key":"2021122309232817700_B42","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial\u2014the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"2021122309232817700_B43","doi-asserted-by":"crossref","first-page":"9133a","DOI":"10.1200\/jco.2010.28.15_suppl.9133","article-title":"Delaying skeletal-related events in a randomized phase III study of denosumab versus zoledronic acid in patients with advanced cancer","volume":"28","author":"Henry","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122309232817700_B44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200624010-00001","article-title":"Bayesian methods for evidence synthesis in cost-effectiveness analysis","volume":"24","author":"Ades","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"2021122309232817700_B45","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: Combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"key":"2021122309232817700_B46","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"2021122309232817700_B47","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2021122309232817700_B48","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"key":"2021122309232817700_B49","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdh173","article-title":"Oral ibandronate for the treatment of metastatic bone disease in breast cancer: Efficacy and safety results from a randomized, double-blind, placebo-controlled trial","volume":"15","author":"Tripathy","year":"2004","journal-title":"Ann Oncol"},{"key":"2021122309232817700_B50","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122309232817700_B51","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"key":"2021122309232817700_B52","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2021122309232817700_B53","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309232817700_B54","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): A phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori","year":"2013","journal-title":"Lancet Oncol"},{"key":"2021122309232817700_B55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta17290","article-title":"Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours","volume":"17","author":"Ford","year":"2013","journal-title":"Health Technol Assess"},{"key":"2021122309232817700_B56","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"2021122309232817700_B57","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122309232817700_B58","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/sj.pcan.4500574","article-title":"Ibandronate in the treatment of prostate cancer associated painful osseous metastases","volume":"5","author":"Heidenreich","year":"2002","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2021122309232817700_B59","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2354.2007.00808.x","article-title":"Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer","volume":"16","author":"Heras","year":"2007","journal-title":"Eur J Cancer Care (Engl)"},{"key":"2021122309232817700_B60","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/j.clinthera.2004.12.010","article-title":"Review of ibandronate in the treatment of metastatic bone disease: Experience from phase III trials","volume":"26","author":"Tripathy","year":"2004","journal-title":"Clin Ther"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2014-0328","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0328","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/4\/440\/41870376\/oncolo_20_4_440.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/20\/4\/440\/41870376\/oncolo_20_4_440.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T02:42:55Z","timestamp":1640313775000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/20\/4\/440\/6399016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,2]]},"references-count":60,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,3,2]]},"published-print":{"date-parts":[[2015,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0328","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,4,1]]},"published":{"date-parts":[[2015,3,2]]}}}